Equities analysts expect that Spero Therapeutics (NASDAQ:SPRO) will report sales of $620,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Spero Therapeutics’ earnings, with the lowest sales estimate coming in at $430,000.00 and the highest estimate coming in at $800,000.00. The firm is scheduled to announce its next earnings results on Thursday, August 9th.
On average, analysts expect that Spero Therapeutics will report full-year sales of $5.39 million for the current fiscal year, with estimates ranging from $1.15 million to $10.38 million. For the next fiscal year, analysts anticipate that the business will post sales of $8.47 million per share, with estimates ranging from $1.15 million to $21.25 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings data on Thursday, May 10th. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.46. The company had revenue of $1.15 million for the quarter, compared to analysts’ expectations of $0.20 million.
SPRO has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Tuesday, January 30th. ValuEngine raised shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Cantor Fitzgerald initiated coverage on shares of Spero Therapeutics in a report on Thursday, February 8th. They set an “overweight” rating and a $27.00 price objective on the stock. Finally, Oppenheimer reissued a “buy” rating on shares of Spero Therapeutics in a report on Tuesday, March 20th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Spero Therapeutics currently has an average rating of “Buy” and a consensus price target of $25.00.
Several hedge funds and other institutional investors have recently made changes to their positions in SPRO. Dean Capital Investments Management LLC purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $118,000. Atlas Venture Associates IX LLC purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $16,179,000. California Public Employees Retirement System purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $294,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $2,830,000. Finally, Artal Group S.A. purchased a new stake in shares of Spero Therapeutics in the fourth quarter valued at about $4,113,000. 46.35% of the stock is currently owned by institutional investors.
SPRO stock opened at $12.10 on Friday. The stock has a market cap of $173.83 million and a P/E ratio of -0.68. Spero Therapeutics has a 52 week low of $9.66 and a 52 week high of $19.00.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.